

Under the High Patronage of
Mr Emmanuel MACRON
President of the French Republic



Paris, 8&9 February 2024

Centre des Congrès Pierre Mendès France
139 Rue de Bercy Paris 12eme

The health industry alliance for research and innovation (ARIIS), the French National Institute of Health and Medical Research (Inserm), the French union of pharmaceutical industries (Leem), the French investment bank (BPI France) and the association of French Healthtech companies (France Biotech) have joined forces to organize

**AN INTERNATIONAL
RESEARCH AND BIOTECHNOLOGY MEETING ON
NEXT GENERATIONS OF GENE AND CELL THERAPIES**

Organized around 4 sessions to address the challenges associated with future viral vectors, genome editing approaches, the various potential uses of nucleic cells, cell-based therapies and immune cell-based therapies and beyond, this meetings is :

An international research and innovation meeting, bringing together academic researchers, start-ups and industry in Paris.

A unique opportunity to discover and meet the best of French research and innovation (research teams, start-ups) and international industrial teams.

A two-day event alternating keynotes, pitches and B to B meetings, paving the way for future collaborations and partnerships with the French innovation ecosystem.

REGISTER NOW: <https://hybridays.com/>



HYBRID: Next generations of gene & cell therapies 8&9 February 2024

Day 1: 8 February 2024

8:00 AM		Welcome Coffee
8:45 AM	Official Speech	Bruno Bonnell, General Secretary for Investment - France 2030 (Prime Minister's Office)
8:55 AM	Opening ceremony	Thomas Lombes (Deputy CEO Inserm); Thierry Hulot (Chairman of Leem) ; Marc Bonneville (Chairman of Ariis), Rosalie Maurisse (Head of Health - Innovation Department at Bpifrance)

Session 1: 9:00 am – 12:45 am

The challenges associated with future viral vectors and genome editing approaches

From the main challenges, avenues and prospects for new vectors to optimized delivery and safety, and tomorrow's genome-editing strategies

Overview	Oumeya Adjali: Gene therapy using AAV viral vectors ; from vector engineering to preclinical evaluation (Nantes University)
Short talks	Ana Buj-Bello: Next generation AAV vectors for gene therapy of muscle disorders (Inserm) Alexis Duvergé: Specific Targeting of Cancer Cells by Lentiviral Vectors (CNRS) Maria Grazia Biferi: Targeting CNS with AAV in a large animal (Spark Therapeutics) <i>Coffee break (10:30-11:00)</i> Annarita Miccio: Genome editing approaches for beta-hemoglobinopathies (Inserm) Aurélie Bedel: How to secure CRISPR-Cas9 use? (University of Bordeaux) Stéphane Boissel: Pioneering Genomics to Save Sight (Sparing Vision)
Round table	Sitra Tausher-Wisniewski (Novartis), Anne Douar (Vivet Therapeutic), Annarita Miccio (Inserm)

Session 2: 03:00pm – 05:30pm

New nucleic acid therapies: applications, vectorization

From prophylactic to therapeutic vaccines and the various potential uses of nucleic acids. Challenges and barriers associated with the uses of nucleic acids: shelf life, route of administration, targeting, etc.

Overviews	Chantal Pichon: The game changing potential of mRNA-based vaccines and therapeutics (University of Orléans) Pierre Wils: From Innovation to Industrialization : Challenges in Research and Development of mRNA Vaccines (Sanofi)
Short talks	Nathalie Mignet: Production of lipid nanoparticles formulations for gene and cell therapy (CNRS) Philippe Barthélémy: Therapeutic oligonucleotides: efficient and specific tools to combat diseases (University of Bordeaux)
Round table	Paul Nioi (Alnylam), Chantal Pichon (Inserm), Anette Sommer (Pfizer), Hélène Tran (Servier), Pierre Wils (Sanofi)

B2B Meetings: 1:00pm – 03:00pm & 5:30pm – 07:00pm

Cocktail reception: 06:00pm – 08:00pm

Day 2: 9 February 2024

8:00 AM		Welcome coffee
8:30AM	Keynotes	Cécile Martinat & Christophe Junot: National research program in biotherapies and bioproduction

Session 3: 8:45 am – 12:15 am Immuno cell based therapies

How can the uses of CAR be extended beyond current applications? How can we improve delivery to solid tumours, the role of the tumour environment, survival, etc.? Applications beyond cancer.

Overview	Tamas Shisha (Novartis): <i>TBA</i>
Short talks	Mitra Suman: Optimizing Adoptive Cellular Therapies in Physio- Chemical Tumor Environments for Superior Anti-Cancer Efficacy without systemic toxicity (Inserm) Emmanuel Donnadiou: Predicting efficacy and toxicity of CAR T cells using an ex vivo human model (CNRS) Marie-Caroline Dieu-Nosjean: Manipulation of tertiary lymphoid structures as the third generation of immunotherapy (Inserm) Georges Lourenço - Discovering novel cancer targets while boosting immune activity to treat solid tumors (Mnemo Therapeutics)
	<i>Coffee break (10:15-10:45)</i>
Round table	Alessandro Crotta (BMS), Emmanuel Donnadiou (CNRS), Sante Cudari (Gilead-Kite), Viggo Van Tendeloo (J&J), Karine Rossignol (SmartImmune)
Keynotes	Lise Alter- The missions of the Health Innovation Agency

Session 4: 2:30pm – 05:30pm Cell therapies and beyond

From the various therapeutic applications of cell therapies to exosomes: how to develop clinical uses of cell therapies, address characterisation issues, etc.? How to take full advantage of the coupling between therapeutic effect and vectorisation properties for exosomes.

Short talks	Louis Casteilla: MSC-based ATMP: present and future (Toulouse University) Christelle Monville: A stem cell therapy pipeline with focus on retinitis pigmentosa and other rare indications with high unmet medical needs (Evry University) Frederic Desdouits: Unlocking cell therapy for all (Treefrog therapeutics) Christian Jorgensen: Next generation cell therapies for osteoarticular diseases (CHU of Montpellier)
Overview	Philippe Menasché: Cell Therapy of Heart Failure: Cells, Exosomes, RNAs? (AP-HP)
Short talks	Gregory Lavieu: Extracellular Vesicle-based vector for targeted therapeutics delivery (Inserm) Jérémy Laurent: Lakhesys, the microfluidics powered benchtop factory for cell & gene therapies to develop better products and solve scalability (Astraveus) Jerome Bonnet: Programming bacteria as smart therapeutics (Inserm)
Keynote	Pr Alain Fischer: Professor at the College of France, President of The French Academy of Science
Conclusion	Marc Bonneville (Head of Ariis)

B2B Meetings: 12:30am – 02:30pm & 05:00pm – 06:30pm